Lineage Cell Therapeutics Inc. — Director's Dealing 2017

Jul 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2017-07-10

Reporting Person: MOHANTY ADITYA P. (Director, Co-Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-07-10	Common Shares, no par value	M	4687	$0.00	Acquired	83958	Direct
2017-07-10	Common Shares, no par value	F	1762	$3.09	Disposed	82196	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-10	Restricted Stock Units	$0.00	M	4687	Disposed		Common Shares (4687)	Direct

Footnotes

F1: Does not include 51,563 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.

F2: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,687 Restricted Stock Units, the grant of which
was previously reported on a Form 4.

F3: Restricted Stock Units vested on July 10, 2017.